Over the last few decades the treatment of multiple sclerosis (MS) has been approached from a number of different perspectives. The initial successes in MS therapy involved the use of corticosteroid treatments to induce short term improvements in neurological function, and symptomatic therapies for ...
Decisions regarding initiation or continuation of disease-modifying therapy for multiple sclerosis have to consider the potential relevance to the pandemic. Understanding the mechanism of action and the possible idiosyncratic effects of each therapeutic agent on the immune system is imperative during this ...
Multiple sclerosis (MS) is a chronic immune-mediated, likely autoimmune disorder characterized by inflammation, demyelination, and neurodegeneration within the central nervous system. Disease-modifying therapies (DMTs) have transformed the management of MS, offering options to modulate the immune system, ...
Multiple sclerosis (MS) is a chronic immune-mediated demyelinating and neurodegenerative disease, and the main disease-modifying treatments rely on modulation or suppression of the immune system Current results show that most drugs to treat MS are linked to an increased risk of infection to varying ...
Disease modifying therapies for relapsing multiple sclerosis. BMJ 2016;354:i3518.Wingerchuk, D.M. and Weinshenker, B.G. (2016) Disease modifying therapies for relapsing multiple sclerosis. BMJ 354, i3518 https://doi.org/10.1136/ bmj.i3518...
Disease-modifying therapy aids cognition in multiple sclerosisNature Clinical Practice Neurology will deliver timely interpretations of key research developments, translating the latest findings into clinical practice. Our Editor-in-Chief and international Advisory Board will ensure comprehensive coverage of ...
Objective: To compare the risk of SARS-CoV-2 infection before and after mass vaccination among patients with multiple sclerosis (pwMS) taking different disease-modifying therapies (DMTs) compared to the general population (GP).Background: Real-world data in the GP show that SARS-CoV-2 vaccines...
INTRODUCTION: There is consensus that exercise represents a behavioral approach for the restoration of function and management of symptoms among persons with multiple sclerosis (MS). The current paper provides a review on the topic of exercise and physical activity as MS-disease modifying treatments. ...
2017. Update on disease-modifying therapies for multiple sclerosis. J Investig Med, 65, 883-91.Vargas DL, Tyor WR (2017) Update on disease-modifying therapies for multiple sclerosis. J Investig Med 65: 883-891.Vargas DL, Tyor WR. Update on disease-modifying therapies for multi...
There are five approved, partially effective, parenteral disease-modifying therapies for multiple sclerosis (MS), including three interferon-beta preparations, glatiramer acetate and the antineoplastic agent mitoxantrone. A sixth drug, natalizumab, was withdrawn from the market in 2005 but could return wi...